Abstract
We studied a newly developed oral quinolone antimicrobial agent, pazufloxacin (PZFX), and obtained the following results
1) Serum and urinary levels of PZFX were determined after oral administration of PZFX 200 mg to 4 aged patients with renal dysfunction. The decrease of serum concentrations of PZFX were correlated with the severity of renal dysfunction (Ccr: 81.6, 63.9, 16.8 and 7.0ml/min). T1/2 was prolonged (4.21, 8.13, 7.05 and 10.81 hours), and AUC0-∞was increased (12.42, 33.51, 61.42 and 53.03μg/ml) with the severity of renal dysfunction. The urinary recovery rates of PZFX were 65.1, 73.2, 71, and 12.1% within the first 24 hrs, with the lowest rate seen in a patient with severe renal dysfunction. PZFX was administered to 36 patients with respiratory tract infection and 1 with urinary tract infection. Clinical response was good in 34 and poor in 3, and the efficacy rate of 91.9%. Laboratory tests revealed elevation of GPT in 1, eosinophilia in 1 and a rise of reticulocyte. However, these findings were slight, and no adverse reaction caused by the drug was observed.
